600535 Tasly Pharmaceutical Group
- 13.93
- +0.23+1.68%
Tasly Pharmaceutical Group News
Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) Stock Goes Ex-Dividend In Just Two Days
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) is about to trade ex-dividend in the next tw
Tasly (600535.SH) will distribute the 2023 cash dividend of 0.33 yuan per share on May 29
Tasly (600535.SH) announced that the company will release the 2023 annual report on May 29, 2024...
Tasly Pharmaceutical Group (SHSE:600535) Seems To Use Debt Rather Sparingly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
Tasly Pharmaceutical Group (SHSE:600535) Is Posting Promising Earnings But The Good News Doesn't Stop There
The market seemed underwhelmed by last week's earnings announcement from Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) despite the healthy numbers. Our analysis suggests that shareholders might b
Tasly Pharmaceutical Group Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models
The analysts might have been a bit too bullish on Tasly Pharmaceutical Group Co., Ltd (SHSE:600535), given that the company fell short of expectations when it released its yearly results last week.
Tasly Pharmaceutical Group Returns to Profit in 2023 as Operating Income Stays Flat
Tasly Pharmaceutical Group (SHA:600535) returned to an attributable profit of 1.07 billion yuan in 2023 from a loss of 264.2 million yuan in 2022, according to a Tuesday filing with the Shanghai Stock
Tasly (600535.SH) reported 2023 annual results, with net profit of 1,071 billion yuan, turning a year-on-year loss into a profit
Tasly (600535.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 86...
Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Top Owners Are Private Companies With 49% Stake, While 41% Is Held by Individual Investors
Key Insights The considerable ownership by private companies in Tasly Pharmaceutical Group indicates that they collectively have a greater say in management and business strategy The top 4 sharehold
Tasilic (600535.SH): Nicordil tablets pass generic drug consistency evaluation
On March 28, Gelonghui (600535.SH) announced that Jiangsu Tianshilidiyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for Nicordil tablets, and approved the drug to pass the consistent evaluation of the quality and efficacy of generic drugs. Nicordil tablets are used to treat angina pectoris and is a category A type of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)”.
Tasly Pharmaceutical Group's (SHSE:600535) Earnings Have Declined Over Five Years, Contributing to Shareholders 11% Loss
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the main game is to find enough winners to more than offset the lo
Tasly Pharmaceutical Gets Nod to Trial Stem Cell Therapy
Tasly Pharmaceutical Group (SHA:600535) will carry out clinical trials on its human umbilical cord mesenchymal stem cell injection after obtaining approval from China's National Medical Products Admin
Tasly (600535.SH): Net profit forecast to increase by 539% to 613% for 2023
Gelonghui, January 18: Tianshili (600535.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, net profit attributable to shareholders of listed companies is expected to be 112.71501 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will increase by 138,366.41 million yuan to 1576.41 million yuan, an increase of 539% to 613% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses is expected to reach 115,5917,900 yuan in 2023
Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Are Not Doing Enough For Some Investors
With a price-to-earnings (or "P/E") ratio of 21.9x Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) may be sending bullish signals at the moment, given that almost half of all companies in China have
Tasly (600535.SH): Termination of sale of shares in a holding subsidiary
On December 29, GLONGHUI (600535.SH) announced that the 22nd meeting of the 8th board of directors of the company held on September 25, 2023 reviewed and passed the “Proposal on Selling Shares in Holding Subsidiaries and Passively Forming External Loans and Guarantees”. Tianjin Tianshili Pharmaceutical Commercial Co., Ltd., a wholly-owned subsidiary of the company, signed a conditionally effective “Equity Acquisition Agreement” with Shuyu Civilian Pharmacy Chain Co., Ltd. and related parties on the same day. The company plans to sell 90% of the shares of Liaoning Tianshilida Pharmacy Chain Co., Ltd. and 60% of the shares of Jinan Pingjiada Pharmacy Co., Ltd. to Shuyu Shuping
Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Largest Shareholders Are Private Companies With 49% Ownership, Individual Investors Own 41%
Key Insights Tasly Pharmaceutical Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
Can Mixed Fundamentals Have A Negative Impact on Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) Current Share Price Momentum?
Tasly Pharmaceutical Group's (SHSE:600535) stock is up by a considerable 16% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on
Tasly Pharmaceutical Group (SHSE:600535) Could Easily Take On More Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
Estimating The Fair Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Tasly Pharmaceutical Group fair value estimate is CN¥17.24 Tasly Pharmaceutical Group's CN¥14.81 share price indicates it is trading at simil
Tensili (600535.SH) released the first three quarter results, with net profit of 1,032 million yuan, turning a loss into a profit
Tianshili (600535.SH) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 65...
Analysis
Price Target
No Data
